Nodify XL2™ testing is designed to help physicians identify likely benign lung nodules using a simple to use blood-based test for patients with low to moderate risk incidental lung nodules.
Nodify XL2 is intended for patients ≥40 years old with low to moderate risk nodules between 8-30 mm with ≤50% risk as assessed by the Solitary Pulmonary Nodule Calculator (Mayo Model)1 .
The Nodify XL2™ blood test helps direct next steps in lung nodule management
We understand the financial stresses that health issues can place on patients. We have created a financial assistance program for patient with financial responsibility to assist in providing affordable care.
To learn more about our financial assistance program, please contact our Customer Care team at 1.866.432.5930.
1. Swensen SJ, Silverstein MD, Ilstrup DM, et. al. "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules." Arch Intern Med. 1997 Apr 28; 157(8):849-55.
2. Silvestri G et al. "Assessment of plasma proteomics biomarkers ability to distinguish benign from malignant lung nodules." CHEST. 2018 Sept. 154(3):491-500.